Reply to: "Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation"

J Hepatol. 2014 Apr;60(4):896-7. doi: 10.1016/j.jhep.2013.11.032. Epub 2013 Dec 4.

Authors

Audrey Coilly¹, Mylène Sebagh², Jean-Charles Duclos-Vallée²

Affiliations

¹ AP-HP, Hôpital Paul Brousse, Centre hépato-Biliaire, Villejuif, France; Inserm, Unité 785, Villejuif, France; Univ Paris-Sud, Villejuif, France; DHU Hepatinov, Villejuif, France. Electronic address: audrey.coilly@pbr.aphp.fr.
² AP-HP, Hôpital Paul Brousse, Centre hépato-Biliaire, Villejuif, France; Inserm, Unité 785, Villejuif, France; Univ Paris-Sud, Villejuif, France; DHU Hepatinov, Villejuif, France.

PMID: 24316027
DOI: 10.1016/j.jhep.2013.11.032

No abstract available

Publication types

Letter
Comment

MeSH terms

Female
Hepatitis C, Chronic / drug therapy*
Humans
Liver Transplantation*
Male
Protease Inhibitors / therapeutic use*

Substances

Protease Inhibitors